cas 98-79-3|| where to buy (2S)-5-oxopyrrolidine-2-carboxylic acid

Nom du produit:(2S)-5-oxopyrrolidine-2-carboxylic acid

IUPAC Name:(2S)-5-oxopyrrolidine-2-carboxylic acid

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM100584-500g	in stock	ƋȌȌ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 98-79-3 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:98-79-3; Formule moléculaire:C5H7NO3; Point de fusion:-; Code SMILES:OC(=O)[C@@H]1CCC(=O)N1; Densité:

: Numéro de catalogue:CM100584; Poids moléculaire:129.12; Point d'ébullition:; N° Mdl:MFCD00005272; Stockage:Store at room temperature.

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Ivosidenib; Tibsovo (ivosidenib tablets) is a precision medicine that targets a specific type of mutation known as isocitrate dehydrogenase 1 (IDH1). Tibsovo is approved in five indications globally, including approvals in the U.S., European Union, Australia, and China.
Tibsovo is the first and only approved targeted therapy for R/R MDS patients with a susceptible IDH1 mutation.
Fifth approved indication for Tibsovo solidifies Servier’s leadership in mutant IDH inhibition.